MAPK3 and neoplasm: For the five identified potential oncomiRs, miR-193a-3p promoted tumor progression by targeting GRB7, ERK1/2, and FOXM1 signaling pathways [59] and PTP1B [60] in HER2-positive breast cancer cells.